You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Residual disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Minimal Residual Disease Using Multi-omics Approach

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
  • Shanghai, China
    Department of Pancreatic and Hepatobiliary Surgery, Fudan Univer
Nov 29, 2023

Minimally Residual of Esophageal Cancer 001

Recruiting
  • Esophageal Carcinoma
  • Minimal Residual Disease
    • Shijiazhuang, Hebei, China
      Fourth Hospital of Hebei Medical University
    Jul 17, 2023

    AML, Adult, Minimal Residual Disease Trial (MRD assessment)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • MRD assessment
    • (no location specified)
    Oct 13, 2023

    Renal Cell Carcinoma Trial in Birmingham (Pembrolizumab injection)

    Not yet recruiting
    • Renal Cell Carcinoma
    • Pembrolizumab injection
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 20, 2023

    GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE

    Enrolling by invitation
    • Pancreatic Adenocarcinoma
    • liquid biopsy
    • Stockholm, Sweden
      Gastrocentrum, KarolinskaUniversity Hospital
    Oct 26, 2023

    MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

    Not yet recruiting
    • Multiple Myeloma
    • Minimal Residual Disease
      • (no location specified)
      Nov 1, 2023

      B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

      Recruiting
      • B-Cell Lymphoblastic Leukemia
      • Acute Lymphoblastic Leukemia
      • Tampa, Florida
        Moffitt Cancer Center
      Nov 28, 2023

      Next-generation Sequencing in Pediatric B-ALL Children Patients

      Not yet recruiting
      • Acute Lymphoblastic Leukemia, Pediatric
      • (no location specified)
      Apr 19, 2023

      Digital Droplet PCR in Early Period After Allo-HSCT to Predict

      Completed
      • Measurable Residual Disease
      • Digital Droplet PCR
      • Hangzhou, Zhejiang, China
        The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
      Aug 17, 2023

      Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)

      Recruiting
      • Minimal Residual Disease
      • Tianjin, Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Nov 3, 2022

      Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • (no location specified)
      Jan 10, 2023

      Pancreatic Cancer, Advanced Cancer, Metastatic Cancer Trial in Beijing (Later-line therapy)

      Recruiting
      • Pancreatic Cancer
      • +2 more
      • Later-line therapy
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Apr 10, 2023

      Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)

      Recruiting
      • Stage II-III Gastric Cancer
      • MRD-guided therapy
      • Jinan, Shandong, China
      • +4 more
      Nov 27, 2023

      Measurable Residual Disease in Acute Myeloid Leukemia as

      Terminated
      • Leukemia, Myeloid, Acute
      • Measurable residual disease measured by flow cytometry
      • Heidelberg, BW, Germany
        University Hospital Heidelberg
      Sep 12, 2022

      Pancreatic Cancer, Resectable Carcinoma Trial in Beijing (Later-line therapy)

      Recruiting
      • Pancreatic Cancer
      • Resectable Carcinoma
      • Later-line therapy
      • Beijing, China
        Department of Medical Oncology, Peking Union Medical College Hos
      Apr 10, 2023

      Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

      Not yet recruiting
      • Ovarian Cancer
      • Houston, Texas
        MD Anderson Cancer Center
      Oct 9, 2023

      Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Trial (Monalizumab, Cetuximab)

      Not yet recruiting
      • Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
      • Monalizumab
      • Cetuximab
      • (no location specified)
      Jan 8, 2023

      Rectal Cancer Patients Based on ctDNA-MRD Technology

      Recruiting
      • Rectal Adenocarcinoma
      • +3 more
      • MRD detection
      • Guangzhou, Guangdong, China
        WeiWei Xiao
      Jul 31, 2023

      Pancreatic Cancer, Locally Advanced Trial in Beijing (Later-line therapy)

      Recruiting
      • Pancreatic Cancer
      • Locally Advanced
      • Later-line therapy
      • Beijing, China
        Department of Medical Oncology, Peking Union Medical College Hos
      Apr 10, 2023

      Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid Trial in Boston (Cytokine Induced Memory-like Natural Killer Cells,

      Not yet recruiting
      • Acute Myeloid Leukemia
      • +5 more
      • Cytokine Induced Memory-like Natural Killer Cells
      • Interleukin-2
      • Boston, Massachusetts
      • +1 more
      Nov 14, 2023

      Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

      Recruiting
      • Leukemia, Myeloid, Acute
      • Minimal Residual Disease
        • Chapel Hill, North Carolina
          North Carolina Cancer Hospital (NCCH)
        Feb 2, 2023

        MDS Trial in Saint Louis (DEC-C, MyeloSeq-HD)

        Recruiting
        • Myelodysplastic Syndromes
        • Saint Louis, Missouri
          Washington University School of Medicine
        Jan 18, 2023

        Leukemia, Lymphoma Trial in Houston (Ofatumumab)

        Active, not recruiting
        • Leukemia
        • Lymphoma
        • Houston, Texas
          University of Texas MD Anderson Cancer Center
        Dec 9, 2022

        Danish Assessment of Minimal Residual Disease by Liquid Biopsies

        Recruiting
        • Colorectal Neoplasms
        • +5 more
          • Copenhagen, Capital Region Of Denmark, Denmark
          • +8 more
          Oct 13, 2023

          Using Mass Spectrometry Detecting Minimal Residual Disease in

          Recruiting
          • Multiple Myeloma
            • Tianjin, China
              InsituteHBDH
            Sep 8, 2022